Last reviewed · How we verify
Ad26.ZEBOV-Batch #1
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection.
Ad26.ZEBOV is a replication-incompetent adenovirus serotype 26 vector expressing the Ebola virus glycoprotein that primes the immune system to recognize and respond to Ebola virus infection. Used for Ebola virus disease prevention.
At a glance
| Generic name | Ad26.ZEBOV-Batch #1 |
|---|---|
| Sponsor | Crucell Holland BV |
| Drug class | Viral vector vaccine |
| Target | Ebola virus glycoprotein (GP) |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
This vaccine uses a non-replicating adenoviral vector to deliver genetic instructions for producing Ebola virus surface glycoprotein, triggering both cellular and humoral immune responses. The Ad26 vector is designed to be safe and immunogenic while avoiding integration into host DNA. It is typically administered as part of a heterologous prime-boost regimen with other Ebola vaccine candidates to enhance protective immunity.
Approved indications
- Ebola virus disease prevention
Common side effects
- Injection site pain or erythema
- Fatigue
- Myalgia
- Headache
- Fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ad26.ZEBOV-Batch #1 CI brief — competitive landscape report
- Ad26.ZEBOV-Batch #1 updates RSS · CI watch RSS
- Crucell Holland BV portfolio CI